| Literature DB >> 31460316 |
Ling Cai1, Xijiang Qin1, Zhihui Xu1, Yiyan Song1, Huijun Jiang1, Yuan Wu2, Hongjie Ruan3, Jin Chen1,4,4.
Abstract
Critical cytotoxicity evaluation of pharmaceuticals is necessary for the clinical practice of chemotherapy. To quantitatively evaluate cell viability, currently there are two main types of sensitive methods including real-time cell analysis (RTCA) and CCK-8 assay, in which RTCA records electrochemical signal changes around an incubated cell, whereas CCK-8 is based on the colorimetric method. Despite the different detection principles adopted for the cytotoxicity assessment, the comparison of the two methods in terms of the application scope is lacking. In this study, comparison studies were conducted between the RTCA and CCK-8 assays using anticancer drugs including doxorubicin hydrochloride, curcumin, irinotecan (CPT-11), taxol, and oxaliplatin, which are classified into two groups of drug molecules in the absence and presence of additives. The cytotoxicity evaluation of these drugs on cancer cells revealed that the physicochemical properties of drug formulations such as optical and electrochemical properties are closely linked with the readout of cytotoxic methods. The experimental results suggested that the preselection of cytotoxic assay is critical for the quantitative measurement of cytotoxicity of anticancer drugs, which is of clinical importance for their therapeutic usage.Entities:
Year: 2019 PMID: 31460316 PMCID: PMC6682106 DOI: 10.1021/acsomega.9b01142
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1UV–vis spectra of 50 μg/mL CCM, irinotecan hydrochloride (CPT-11), DOX, taxol, and oxaliplatin.
Figure 2Cell viability of HeLa induced by DOX (A) and CCM (C) after 24 h by CCK-8 assay; cell growth curve of HeLa induced by DOX (B) and CCM (D) by RTCA.
Figure 3(A) Cell viability of HeLa induced by CPT-11 after 48 h incubation by CCK-8 assay; (B) cell growth curve of HeLa induced by CPT-11 monitored by RTCA; (C) electrochemical impendence spectra of GCEs modified with HeLa cells only, the cells containing 12.5 and 50.0 μg/mL CPT-11, respectively.
Figure 4Cell viability of HeLa induced by taxol (A) and oxaliplatin (C) after 48 h in CCK-8 assay; cell growth curve of HeLa induced by taxol (B) and oxaliplatin (D) in RTCA.
Figure 5Cell viability of HeLa cells induced by DOX (A) and CCM (B) after 24 h and treated with CPT-11 (C), taxol (D), and oxaliplatin (E) after 48 h in cell counting assays.
Cytotoxicity of Anticancer Drugs (IC50) Obtained by CCK-8 and RTCA Assays
| IC50 (μg/mL) | ||||
|---|---|---|---|---|
| HeLa | A549 | |||
| drug | CCK-8 | RTCA | CCK-8 | RTCA |
| doxorubicin | 0.368 ± 0.059 | 0.364 | ||
| CCM | 27.0 ± 2.40 | 10.6 | 24.0 | 9.61 |
| CPT-11 | 35.5 ± 6.51 | 17.2 | ||
| taxol | 1.08 ± 0.016 | 1.07 | ||
| oxaliplatin | 16.5 ± 0.334 | 17.1 | ||
CCK-8 assay was conducted in triplicate to ensure the accuracy. CPT-11: irinotecan hydrochloride.